Replies to post #146447 on Biotech Values

[DewDiligence]

(HALO)—BAX resubmits BLA for HyQvia (enhanced IVIG):

http://finance.yahoo.com/news/baxter-submits-amended-bla-u-140000366.html

HyQvia is a combination of human immune globulin and recombinant human hyaluronidase. Baxter and Halozyme submitted additional preclinical data that was requested from the FDA in [August] 2012, and expect a six-month review period.